Skip to main content
. 2020 Feb 21;9(5):e014397. doi: 10.1161/JAHA.119.014397

Figure 4.

Figure 4

Administration of mesenchymal stem cells ameliorate myocardial I/R injury and improve cardiac function. A, Quantification of AAR, infarct size and infarct size/AAR through TTC/Evans Blue staining. AAR was similar between groups. Infarct size and the percentage of infarct size/AAR were significantly decreased in mesenchymal stem cell 0‐hour and mesenchymal stem cell 24‐hour groups. Mesenchymal stem cell 0‐hour group was the most significant. Area at risk was stained as red (green arrow), and infarct area was stained as white (yellow arrow). (n=5,6, or 4 in each group). B, Left ventricular fractional shortening and ejection fraction. (n=6). C, +dp/dtmax and −dp/dtmin first derivative of left ventricular pressure rise and fall. (n=6). AAR indicates area at risk; LVEF, left ventricular ejection fraction; LVFS, left ventricular shortening fraction; MI/R, myocardial ischemia reperfusion; MSC, mesenchymal stem cells; TTC indicates 2,3,5‐triphenyltetrazolium chloride. (Data are presented as mean±SD, ***P<0.001 vs sham, # P<0.05 vs MI/R, ## P<0.01 vs MI/R, ### P<0.001 vs MI/R, $$ P<0.01 vs MSC 0‐hour, ANOVA with Tukey post hoc test).